This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Surescripts says US FTC antitrust suit failed to show foreclosure, anticompetitive effects in e-prescription markets

( August 3, 2022, 12:00 GMT | Official Statement) -- MLex Summary: The US Federal Trade Commission "cannot prove that a single competitor was foreclosed from entering the market" by Surescripts’ loyalty provisions for e-prescription eligibility and routing services, the company said in a motion for summary judgment filed in District of Columbia federal court. The FTC "has not presented any evidence" that Surescripts' optional loyalty provisions have caused anticompetitive effects in those same markets, the motion said.Court document attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections